Novo Nordisk Taps Anthropic's Claude to Speed Drug Discovery

Novo Nordisk and Anthropic announced a collaboration on September 16, 2026, in which the Danish drugmaker will use Anthropic's frontier models and test the Claude Science workbench in specific research and development workflows, with the stated goal of accelerating the discovery and development of new medicines. The announcement was datelined Bagsværd, Denmark.

The two companies say they will jointly address key drug discovery challenges identified by scientists and computational teams at Novo Nordisk and develop targeted solutions for specific scientific problems and workflows that support biological reasoning. As an initial aim, Novo Nordisk will test Claude Science for specific R&D workflows, focusing on problems where the partners' combined capabilities are expected to have the greatest impact.

Beyond the lab, Novo Nordisk will also use Anthropic's frontier models to strengthen AI-driven software development, which the companies describe as a key enabler for scaling AI across the company. They say the collaboration was designed with robust data governance and human oversight so that AI is applied responsibly and in line with Novo Nordisk's ethical and compliance standards.

Mike Doustdar, Novo Nordisk's president and CEO, called the partnership another testament to the company's ambition to become the world's most AI-driven healthcare company, pointing to existing AI initiatives with other technology partners. He said joining forces with Anthropic will supercharge its R&D organisation and help it bring new treatments to people living with chronic diseases. Dario Amodei, Anthropic's co-founder and CEO, said AI's increasing capability brings the potential to compress a century's worth of biological and medical breakthroughs into a decade, and that giving leading researchers safe, capable and trusted frontier models can shorten research timelines.

Claude Science is not a new model: introduced in beta on June 30, 2026, it is a public beta application that runs the same Claude models included in a user's plan and adds scientific tools, database connections and compute integrations around them.

In Anthropic's description, users work through a generalist coordinating agent with access to more than 60 curated skills and connectors pre-configured for genomics, single-cell analysis, proteomics, structural biology and cheminformatics, and those agents can spin up additional agents and engage specialist agents created by users. A reviewer agent checks citations and calculations, and every output carries an auditable history: the exact code, the environment, a plain-language description and the full message history. The app runs on the user's own infrastructure, so large or sensitive datasets do not have to leave existing systems, and it connects natively to more than 60 scientific databases, reaching life sciences models such as Evo 2, Boltz-2 and OpenFold3 through NVIDIA's BioNeMo Agent Toolkit.

Novo Nordisk is not starting from zero. An Anthropic case study describes NovoScribe, a documentation platform the drugmaker built with Claude Code on Amazon Bedrock and MongoDB Atlas, pairing retrieval-augmented generation with domain expert-approved text and case-specific variables to produce regulatory documentation.

That case study reports the time spent producing clinical study documentation fell from more than ten weeks to ten minutes and the resources needed to create device verification protocols dropped by 95%, while writing times on clinical study reports were cut by 90%. Such reports can run up to 300 pages, and staff writers previously averaged 2.3 of them a year. Novo Nordisk's stated goal is to automate production of full Common Technical Documents, the comprehensive regulatory submissions required for drug approval.

Pharma is one of the most data-sensitive and heavily regulated sectors, and Claude Science's design, which runs on the customer's own infrastructure with a full audit trail, maps directly onto those compliance requirements. The things to watch are whether Novo Nordisk moves the pilot beyond clinical study reports toward complete Common Technical Documents, and whether claims about compressing R&D timelines eventually show up in clinical data.